Kronos reported record third-quarter 2026 net revenue of $63.5 million, up 75% year-over-year, with record adjusted EBITDA of $17.1 million.
CRON · Cronos Group Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Cronos reported third-quarter net revenue of $63.5 million, up $27.1 million, and gross profit of $32.3 million, up $14.0 million. Nine-month net revenue was $161.7 million and gross profit $79.9 million.
Cronos Group Inc. reported Q3 2026 net revenue of $63.5 million, up 75% year-over-year and 73% organically on a constant-currency basis, with Adjusted EBITDA of $17.1 million.
Cronos Group Inc. completed its acquisition of CanAdelaar on October 15, 2026, making it a wholly owned subsidiary for a base purchase price of €57.5 million, subject to adjustments, plus cash earnouts tied to 2026 and 2027 Normalised EBITDA.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Q3 net revenue rose to $63.5 million and Adjusted EBITDA reached a record $17.1 million, with gross profit up $14.0 million. Net income fell to $17.8 million as operating expenses rose to $23.3 million, and price compression and lumpy international sales remain risks.
- + Q3 net revenue of $63.5 million, up $27.1 million year-over-year, driven by flower sales in Israel and other countries. new
- + Adjusted EBITDA of $17.1 million, a record, improved by $11.4 million year-over-year on higher gross profit. new
- + Gross profit of $32.3 million, up $14.0 million year-over-year, driven by higher average sales prices and volumes. new
- + International business ex-Israel delivered record net revenue, increasing 614% year-over-year, led by Germany. new
- + Cronos Israel delivered its eleventh consecutive quarter of record net revenue, up 33% year-over-year (19% on a constant-currency basis). new
- + Completed the acquisition of CanAdelaar B.V. on October 15, 2026, establishing a leadership position in Europe's largest adult-use cannabis market. new
- − Net income of $17.8 million, down from $28.3 million a year earlier, on lower other income, higher operating expenses and a tax provision. new
- − Total operating expenses of $23.3 million, up $4.4 million year-over-year, driven by G&A and sales and marketing. new
- − Seasonal softness in Canadian Provincial Board purchasing is expected in Q4 versus Q3, and international sales can be lumpy. new
- − Gross margins may vary due to potential price compression, mix and production volumes. new
- − Management expects price compression in the Netherlands market now that suppliers have ramped up. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $18.17M | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted Gross Margin non-GAAP | 48% | Six months ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | $47.6M | Six months ended June 30, 2026 | — |
|
|
|||
| Cronos Israel net revenue growth year-over-year | 60% | Q2 2026 | — |
| Shares repurchased | 12.3M | First half of 2026 | — |
| Spinach disposable vape market share | 8.2% | Q2 2026 | — |
| Spinach edibles market share | 20.8% | Q2 2026 | — |
| Spinach flower market share | 5.4% | Q2 2026 | — |
| Spinach infused pre-rolls market share | 3.5% | Q2 2026 | — |
| Spinach national market share | 5.9% | Q2 2026 | — |
| Spinach pre-rolls market share | 3.1% | Q2 2026 | — |
| Spinach total vape market share | 10.6% | Q2 2026 | — |
| Spinach vape cartridge market share | 11.8% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRON
this stock
Cronos Group Inc.
|
$1.17B | +21.3% | +24.6% | 19.9 | 1.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$69.14B | +38.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$52.00B | +7.6% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.73B | +36.6% | +4.3% | 96.9 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 16
Cronos reported third-quarter net revenue of $63.5 million, up $27.1 million, and gross profit of $32.3 million, up $14.0 million. Nine-month net revenue was $161.7 million and gross profit $79.9 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRON | -6.5% | -2.7% | +12.3% | -3.3% | +21.3% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -4.1% | +2.0% | +15.3% | -0.3% | +13.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.